Drug Trial Radar · NCT05449535
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jun 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
May 7, 2022
Primary completion
Jan 10, 2023
Study completion Jan 10, 2023
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.
Conditions
- Healthy
Interventions
JYB1904Drug
Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
OmalizumabDrug
Dosage form: injection, powder, lyophilized, for solution; Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
JYB1904 PlaceboDrug
Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Baseline through 168 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shulan (Hangzhou) Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.